• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Decreased Hospital Length of Stay With Early Administration of Oseltamivir in Patients Hospitalized With Influenza

tetano

Editor, Senior Moderator
Mayo Clin Proc Innov Qual Outcomes. 2020 Apr 6;4(2):176-182. doi: 10.1016/j.mayocpiqo.2019.12.005. eCollection 2020 Apr.
Decreased Hospital Length of Stay With Early Administration of Oseltamivir in Patients Hospitalized With Influenza.


Dou L[SUP]1[/SUP], Reynolds D[SUP]2[/SUP], Wallace L[SUP]3[/SUP], O'Horo J[SUP]4,[/SUP][SUP]5[/SUP], Kashyap R[SUP]5[/SUP], Gajic O[SUP]5[/SUP], Yadav H[SUP]5[/SUP].

Author information




Abstract

Objective:

To evaluate the effects of timely oseltamivir administration in patients hospitalized with seasonal influenza.
Patients and Methods:

We performed a single-center retrospective cohort study for hospitalized patients who tested positive for influenza between December 1, 2010, and July 1, 2014. We compared outcomes for patients who received antivirals within 48 hours of symptoms to those of patients who either received oseltamivir after 48 hours or never received oseltamivir. Hospital length of stay (LOS) and 90-day mortality were compared using Cox regression models. Antiviral administration was analyzed as a time-varying covariate.
Results:

During the study period, 433 patients were hospitalized with laboratory-confirmed influenza. Of these patients, 146 (33.7%) received oseltamivir within 48 hours of symptoms, 202 (46.7%) received oseltamivir after 48 hours of symptoms, and 85 (19.6%) did not receive antivirals. Baseline characteristics were similar among these patient groups. Receiving oseltamivir within 48 hours was associated with shorter hospital LOS (5.9 days vs 7.2 days; P=.03) but no significant difference in 90-day mortality (13.7% vs 11.5%; P=.51). In a Cox regression analysis, patients who received antivirals within 48 hours had a 50% higher chance of being discharged (hazard ratio, 1.50; 95% CI, 1.14-1.98) on any given day during hospital stay.
Conclusion:

In patients hospitalized with laboratory-confirmed influenza, timely administration of oseltamivir was associated with shorter hospital LOS.
? 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.



KEYWORDS:

HR, hazard ratio; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay; NAI, neuraminidase inhibitor; PCR, polymerase chain reaction


PMID:32280928PMCID:PMC7139986DOI:10.1016/j.mayocpiqo.2019.12.005
Free full text
 
Back
Top Bottom